Current treatment strategies in low-risk myelodysplastic syndromes

Cancer Treatment Reviews

Volumn 33, Issue SUPPL. 1, 2007, Pages

  Giagounidis, Aristoteles A N ^a   Germing, Ulrich ^b   Aul, Carlo ^a  

^a ST JOHANNES HOSPITAL   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

ATG; Best supportive care; Deferasirox; Erythropoietin; Lenalidomide; Myelodysplastic syndrome; Thalidomide; Valproic acid

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMINOGLYCOSIDE; AZACITIDINE; BETA LACTAM; CYCLOSPORIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE ACETYLTRANSFERASE; HLA DR15 ANTIGEN; LENALIDOMIDE; QUINOLONE DERIVATIVE; RETINOIC ACID; THALIDOMIDE; THYMOCYTE ANTIBODY; VALPROIC ACID;

5Q- SYNDROME; ADD ON THERAPY; AGRANULOCYTOSIS; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; CONSTIPATION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; IRON CHELATION; IRON OVERLOAD; MAXIMUM PERMISSIBLE DOSE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; POLYNEUROPATHY; PROGNOSIS; RISK ASSESSMENT; SCORING SYSTEM; THROMBOCYTOPENIA;

EID: 35848958149     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.07.005     Document Type: Article

References (43)

1. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
2. Aul C., Giagounidis A., Heinsch M., Germing U., and Ganser A. Prognostic indicators and scoring systems for predicting outcome in patients with myelodysplastic syndromes. Rev Clin Exp Hematol 8 (2004) E1
3. Oliva E.N., Dimitrov B.D., Benedetto F., D'Angelo A., and Nobile F. Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk Res 29 (2005) 1217-1219
4. Kalmadi S., Tiu R., Lowe C., Jin T., and Kalaycio M. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer 107 (2006) 136-140
5. Porter J.B. Practical management of iron overload. Br J Haematol 115 (2001) 239-252
6. Andrews N.C. Disorders of iron metabolism. N Engl J Med 341 (1999) 1986-1995
7. Schafer A.I., Cheron R.G., Dluhy R., et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 304 (1981) 319-324
8. Jaeger M., Aul C., Sohngen D., Germing U., and Schneider W. Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes. Beitr Infusionsther 30 (1992) 464-468
9. Porter J.B. Deferoxamine pharmacokinetics. Semin Hematol 38 Suppl 1 (2001) 63-68
10. Jensen P.D., Heickendorff L., Pedersen B., et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 94 (1996) 288-299
11. Neufeld E.J. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 107 (2006) 3436-3441
12. Cohen A.R., Galanello R., Piga A., De Sanctis V., and Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 102 (2003) 1583-1587
13. Martin M.G., and Arcasoy M.O. Deferasirox versus deferoxamine. Blood 108 (2006) 774-775 author reply 775-6
14. Schimpff S.C., Young V.M., Greene W.H., Vermeulen G.D., Moody M.R., and Wiernik P.H. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med 77 (1972) 707-714
15. Engels E.A., Lau J., and Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 16 (1998) 1179-1187
16. Cruciani M., Rampazzo R., Malena M., et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 23 (1996) 795-805
17. Richard P., Delangle M.H., Merrien D., et al. Fluoroquinolone use and fluoroquinolone resistance: is there an association?. Clin Infect Dis 19 (1994) 54-59
18. Hellstrom-Lindberg E. Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents. Hematology (Am Soc Hematol Educ Program) (2005) 161-166
19. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 1998;103:1070-4.
20. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120 (2003) 1037-1046
21. Howe R.B., Porwit-MacDonald A., Wanat R., Tehranchi R., and Hellstrom-Lindberg E. The WHO classification of MDS does make a difference. Blood 103 (2004) 3265-3270
22. Hamblin T.J. The management of anemia in the myelodysplastic syndrome. Leuk Res 29 (2005) 1101-1102
23. Jadersten M., Montgomery S.M., Dybedal I., Porwit-MacDonald A., and Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 106 (2005) 803-811
24. Mannone L., Gardin C., Quarre M.C., et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 133 (2006) 513-519
25. Jonasova A., Neuwirtova R., Cermak J., et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 100 (1998) 304-309
26. Shimamoto T., Tohyama K., Okamoto T., et al. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leuk Res 27 (2003) 783-788
27. Tichelli A., Gratwohl A., Wuersch A., Nissen C., and Speck B. Antilymphocyte globulin for myelodysplastic syndrome. Br J Haematol 68 (1988) 139-140
28. Biesma D.H., van den Tweel J.G., and Verdonck L.F. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 79 (1997) 1548-1551
29. Molldrem J.J., Caples M., Mavroudis D., Plante M., Young N.S., and Barrett A.J. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 99 (1997) 699-705
30. Asano Y., Maeda M., Uchida N., et al. Immunosuppressive therapy for patients with refractory anemia. Ann Hematol 80 (2001) 634-638
31. Steensma D.P., Dispenzieri A., Moore S.B., Schroeder G., and Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 101 (2003) 2156-2168
32. Stadler M., Germing U., Kliche K.O., et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 18 (2004) 460-465
33. Saunthararajah Y., Nakamura R., Wesley R., Wang Q.J., and Barrett A.J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 102 (2003) 3025-3027
34. Kuendgen A., Strupp C., Aivado M., et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104 (2004) 1266-1269
35. Estey E.H. Modulation of angiogenesis in patients with myelodysplastic syndrome. Best Pract Res Clin Haematol 17 (2004) 623-639
36. Musto P. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res 28 (2004) 325-332
37. Raza A., Meyer P., Dutt D., et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98 (2001) 958-965
38. Strupp C., Germing U., Aivado M., Misgeld E., Haas R., and Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16 (2002) 1-6
39. Mitsiades C.S., and Mitsiades N. CC-5013 (Celgene). Curr Opin Investig Drugs 5 (2004) 635-647
40. List A., Kurtin S., Roe D.J., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352 (2005) 549-557
41. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355 (2006) 1456-1465
42. Giagounidis A.A., Germing U., Strupp C., Hildebrandt B., Heinsch M., and Aul C. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol 84 (2005) 569-571
43. Raza A., List A., Bennett J., et al. Lenalidomide (CC5013)-induced red blood cell (RBC) transfusion-independence (TI) responses in low-/int-1 risk patients with myelodysplastic syndromes (MDS): results of the multicenter MDS 002 study. Leukemia Res 29 (2005) S70